IQVIA Holdings Inc. (NYSE:IQV) is one of the 10 Best Diagnostics and Research Stocks to Buy According to Analysts.

On March 9, 2026, TD Cowen upgraded its rating on IQVIA Holdings Inc. (NYSE:IQV) from Hold to Buy. Along with the rating upgrade, the firm also raised its price target on the stock from $174 to $213. The company is anticipated to remain resilient against AI-driven revenue headwinds, according to TD Cowen analysts. It further noted that AI could potentially reduce drug trial costs by 10% to 15%, but these savings are expected to be further reinvested into research activity. Following a 24% share price decline since February, TD Cowen sees an attractive risk-reward opportunity.

Prior to this, in an unrelated event, Barclays also upgraded IQVIA Holdings Inc. (NYSE:IQV)’s rating from Equal Weight to Overweight, while maintaining a price target of $210. The firm’s analyst anticipates an upside for the stock, projecting higher valuations and financial estimates. It added in a research note that the consistency in its execution justifies a premium market valuation for IQVIA Holdings Inc. (NYSE:IQV).

Founded in 1982, IQVIA Holdings Inc. (NYSE:IQV) is a global leader in clinical research and health data, headquartered in North Carolina.

While we acknowledge the potential of IQV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best Stocks to Invest in During a Recession and 10 Best Space Exploration Stocks to Buy According to Analysts

Disclosure: None. Follow Insider Monkey on Google News.